Fatigue News and Research

RSS

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

A Special Focus Issue on Integrative Oncology takes a wide-ranging view of the possible approaches and potential therapeutic benefits of complementary and integrative medicine in multiple age groups, nations, and special populations.

25 Sep 2018

Study: Optimizing dopaminergic treatment improves non-motor symptoms and quality of life

Non-motor symptoms are common in late-stage Parkinson's disease as the frequency and severity of most of these symptoms increase with advancing disease. Optimizing dopaminergic treatment in the most severe stages can affect non-motor symptoms and improve quality of life, report scientists in the Journal of Parkinson's Disease.

25 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Researchers find impact of neurobehavioral symptoms on employment in adults with TBI

Kessler Foundation researchers have published their findings linking behavioral symptoms with employment outcomes among adults with moderate to severe traumatic brain injury.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Researchers develop technology to study behavior of implants without animal testing

An international team of researchers consisting of scientists from NUST MISIS and TU Dortmund University has developed a technology to study the behavior of orthopedic implants in laboratory conditions as close as possible to the human body.

21 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Older individuals with multiple sclerosis report higher quality of life than younger counterparts

A recent brief report by MS researchers provides preliminary evidence that older individuals with multiple sclerosis report lower levels of depression and higher quality of life than their younger counterparts.

20 Sep 2018

More doctor visits can lower risk of suicide attempts in fibromyalgia patients

Fibromyalgia patients who regularly visit their physicians are much less likely to attempt suicide than those who do not, according to a new Vanderbilt University Medical Center study published in Arthritis Care & Research.

19 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Processing speed important to higher order cognitive function in multiple sclerosis patients

A recent article by Kessler Foundation researchers underscores the importance of processing speed in overall cognitive function in individuals with multiple sclerosis and their performance of everyday life activities.

19 Sep 2018

Researchers study neuronal activity in brain that prevents individuals from doing physical activity

About 30% of adults and 80% of teenagers today do not meet the minimum levels of daily physical activity for staying healthy, as recommended by the World Health Organisation.

18 Sep 2018

Researchers find new way to differentiate between active and inactive viruses

Human herpesviruses such as HHV-6 can remain dormant in cells for many years without being noticed. When reactivated, they can cause serious clinical conditions. Researchers from Würzburg have now found a way of differentiating between active and inactive viruses.

14 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Fatigue News and Research

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

Study: Optimizing dopaminergic treatment improves non-motor symptoms and quality of life

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Researchers find impact of neurobehavioral symptoms on employment in adults with TBI

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Researchers develop technology to study behavior of implants without animal testing

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Older individuals with multiple sclerosis report higher quality of life than younger counterparts

More doctor visits can lower risk of suicide attempts in fibromyalgia patients

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Processing speed important to higher order cognitive function in multiple sclerosis patients

Researchers study neuronal activity in brain that prevents individuals from doing physical activity

Researchers find new way to differentiate between active and inactive viruses

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Second case of Monkeypox infection identified in UK

Smart technology and AI could help improve detection of sepsis in children in Canada

New guidelines for TBI incorporate insights from rehabilitation professionals

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News